The combined effect of vitamin D and zinc on premenstrual syndrome

Phase 3

Recruiting

Conditions: Premenstrual Syndrome (PMS).
Premenstrual tension syndrome
N94.3

Registration Number: IRCT20090901002394N47

Lead Sponsor: Iran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Female

Target Recruitment: 96

Inclusion Criteria

Single women with a regular menstrual cycle between 24 and 35 days
The suitable age for the study is 18-30 years old
BMI of the studied women is between 18.5 and 24.9
Not taking any contraceptive pills
Not taking anti-inflammatory, anti-depressant and psychotic drugs
Not doing sports professionally
Not taking vitamin D and zinc supplements for 3 months before starting the study
Willingness, satisfaction and ability to carry out and complete the study and cooperate with the research

Exclusion Criteria

Being married
Having vitamin D deficiency
Suffering from an endocrine disorder such as thyroid failure, polycystic ovary syndrome and diabetes mellitus
History of gynecological disorders
History of autoimmune diseases
Suffering from chronic and acute diseases (acute or chronic kidney failure, acute or chronic liver failure, chronic inflammatory disease or any known malignancy)
Having irregular menstrual cycles (Less than 24 days and more than 35)
Having stress caused by the death of relatives, surgery or marriage in the previous three months
History of psychiatric diseases

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Depression score in Beck's Depression Inventory. Timepoint: At baseline and after8 weeks. Method of measurement: Beck's Depression Inventory.;Depression score in Beck Anxiety Inventory. Timepoint: At baseline and after8 weeks. Method of measurement: Beck Anxiety Inventory.;The score of The premenstural symptoms screening tool (PSST). Timepoint: At baseline and after8 weeks. Method of measurement: The premenstural symptoms screening tool (PSST).;The levels of total antioxidant capacity. Timepoint: At baseline and after8 weeks. Method of measurement: ELISA Kit.

Secondary Outcome Measures

Name	Time	Method
Weight. Timepoint: At baseline and after8 weeks. Method of measurement: Scale.;Body mass index. Timepoint: At baseline and after8 weeks. Method of measurement: Calculation.;Waist circumference. Timepoint: At baseline and after8 weeks. Method of measurement: Measuring tape.